Regeneron Pharmaceuticals, Inc. is engaged in the discovery, invention, development, manufacturing, and commercialization of medicines for a range of diseases globally. The operating income ratio is 0.28 indicating the company's operational profitability margin. Its diverse product range includes EYLEA, which is used to treat conditions such as wet age-related macular degeneration and diabetic macular edema, alongside treatments for myopic choroidal neovascularization and various forms of diabetic retinopathy. The company also develops and markets Dupixent for atopic dermatitis and asthma in both adults and children, Libtayo for specific cancers, and Praluent for managing familial hypercholesterolemia and cardiovascular disease. Moreover, REGEN-COV is available for treating COVID-19, while Kevzara addresses rheumatoid arthritis in adults. Regeneron has also made strides in treating Zaire ebolavirus infections through Inmazeb and offers ARCALYST for various periodic syndromes, including familial cold auto-inflammatory syndrome. Furthermore, ZALTRAP is indicated for metastatic colorectal cancer, as the company continually innovates therapies for eye, allergic, inflammatory, cardiovascular, metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions. The net income ratio stands at 0.31 reflecting the company's profitability margin, while the reported income before tax is 4,779,900,000.00 showcasing its pre-tax profitability. Additionally, the earnings per share (EPS) is reported at $40.90 indicating the company's profitability on a per-share basis. The company earned an interest income of $711,400,000.00 showcasing its financial investments. With a large market capitalization of $77,328,504,310.00 Regeneron is a dominant player in the biopharmaceutical industry, contributing significantly to the overall market landscape. The stock is priced at $591.99 positioning it in the higher-end market, and it has an average trading volume of 1,081,829.00 indicating moderate liquidity. As a key player in the Biotechnology industry, Regeneron drives innovation and growth, establishing its presence in the Healthcare sector. The company's collaborative efforts through various agreements with notable partners and institutions further reinforce its strategic positioning and commitment to advancing healthcare solutions.